CFO Kim Paul bought 100,000 FLGT shares at $15.96 (+40.3% of holdings) amid -2.0% annual revenue decline and $-14.6M net loss.
Kim Paul, CFO and Treasurer, purchased 100,000 shares (348.3K shares post-transaction) at $15.96, increasing her holdings by 40.3% relative to pre-transaction levels. Notably, this acquisition occurs while Fulgent Genetics reported negative full-year net income of $-14.6M and faced annual revenue decline of -2.0%, making the company unprofitable in its most recent fiscal year. The stock is trading at $16.65, down 33.6% from its 52-week high of $25.06 and down 15.5% over the 90-day period, though up 2.0% in the last 30 days. The substantial increase in the CFO's stake in an unprofitable company warranting careful monitoring—whether it reflects confidence in near-term turnaround prospects or other motivations requires deeper analysis of forward guidance and the broader context of the transaction timing.